Clinical Trial Search

Primary: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) After Single Dosing With Preladenant for Participants With Severe CRI Versus Healthy Matched…

Primary: Side Effect of Cadaveric Donor Liver NK Cell Infusion — 0; 0 participants

Primary: Number of Participants With Grade 2 or Higher Adverse Event According to NCI Criteria — 0 participants

Primary: Pharmacokinetics: Maximum Concentration (Cmax) of Dulaglutide — 29.4; 44.2; 81.5; 20.7 nanograms per milliliter (ng/mL)

Primary: Estimated Area Under the Liver Concentration-time Curve for 24 Hours Post-dose (AUC[H]0-24hr) of Grazoprevir — 19800 µM*hr

Primary: Area Under the Concentration-time Curve From 0 to 24 Hours Postdose (AUC0-24hr) of Grazoprevir — 0.969; NA; NA; 0.944 uM*hr

Primary: Area Under the Concentration Time-curve From 0 to 24 Hours (AUC0-24) of Grazoprevir — 1.71; 1.42; 1.61; 0.321 uM*hr

Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUCinf] — 10690; 3187; 2725; 3430 nanogram*hour/milliliter (ng*hr/mL)

Primary: Determine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary Atresia — 10; 0; 0; 0 participants

Primary: Adjusted Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Apixaban — 236; 249; 186 ng/mL

Primary: Safety — 10 participants

Primary: Number of Participants With Clinical and Laboratory Adverse Events (AEs) — 6; 3; 13; 4 Participants

Primary: Numeric Rating Scale (NRS) Pain Score With Movement — 1.9; 1; 1.3 units on a scale

Primary: AUC0-72h (Part II) — 2740; 3050; 2800 nmol*h/L

Primary: Number of Participants With One or More Adverse Events (AEs) — 5; 3; 3; 4 Participants